Clinical Trials Browser

Phase 3 × Completed × Pemetrexed × Clear all

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 2 FDA

Uterine Cervical Neoplasms

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03829319 2026-02-05

LEAP-006

Phase 3 Completed

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05226598 2026-02-05

MK-7684A-007

Phase 3 Completed

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Phase 3 Completed

Non-Small-Cell Lung

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04716933 2025-09-09

LEAP-006

Phase 3 Completed

201 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT01951482 2025-08-17

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

Phase 3 Completed

Brain Neoplasms

NCT00284778 2025-07-24

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00324805 2025-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Phase 3 Completed

1,501 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT01828112 2025-02-07

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Phase 3 Completed

231 enrolled 33 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03663205 2025-02-04

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Phase 3 Completed

334 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02576574 2025-01-31

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3 Completed

1,214 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Phase 3 Completed

376 enrolled 34 charts 2 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00418886 2024-12-31

ZEAL

Phase 3 Completed

698 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03515837 2024-11-22

MK-3475-789

Phase 3 Completed

492 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02578680 2024-09-20

MK-3475-189

Phase 3 Completed

616 enrolled 19 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04194203 2024-07-19

A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT03950674 2024-06-10

MK-3475-189

Phase 3 Completed

40 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 3 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT03802240 2023-11-27

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Phase 3 Completed

Non-Squamous Non-Small Cell Lung Cancer

NCT02657434 2023-11-21

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Phase 3 Completed

578 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT02220894 2023-10-10

Keynote 042

Phase 3 Completed

1,274 enrolled 23 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02864251 2023-09-28

CheckMate722

Phase 3 Completed

367 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03850444 2023-09-18

Keynote 042

Phase 3 Completed

262 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT01454934 2023-06-22

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Phase 3 Completed

540 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02409342 2023-03-15

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3 Completed

572 enrolled 32 charts 3 FDA

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

NCT01850303 2023-03-14

MODEL

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02041533 2023-03-02

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Phase 3 Completed

541 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03607539 2023-02-27

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3 Completed

397 enrolled 15 charts

Lung Neoplasms

NCT02142738 2022-06-13

MK-3475-024

Phase 3 Completed

305 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT00982111 2022-01-11

INSPIRE

Phase 3 Completed

633 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT00948675 2021-10-29

Study of Participants With Advanced Non-Small Cell Lung Cancer

Phase 3 Completed

361 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02367781 2021-08-09

IMpower130

Phase 3 Completed

723 enrolled 28 charts 2 FDA

Carcinoma

NCT02264990 2021-02-26

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Phase 3 Completed

595 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01639001 2020-12-08

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Phase 3 Completed

207 enrolled 29 charts

Carcinoma, Non-Small-Cell Lung

NCT01544179 2020-09-25

IMPRESS

Phase 3 Completed

265 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT03134872 2020-06-09

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Phase 3 Completed

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02604342 2019-10-29

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Phase 3 Completed

119 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT00078260 2019-09-12

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT00087711 2019-09-12

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT02900742 2019-04-12

Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer

Phase 3 Completed

Lung Neoplasms, Neoplasms

NCT00789373 2018-12-14

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer

Phase 3 Completed

939 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01631136 2018-01-17

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT01351415 2017-09-18

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3 Completed

485 enrolled 15 charts

Non-Squamous Non-Small Cell Lung Cancer